Literature DB >> 12907447

Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect.

Emiko Sakaida1, Chiaki Nakaseko, Akane Harima, Akira Yokota, Ryuko Cho, Yasushi Saito, Miki Nishimura.   

Abstract

Late-onset noninfectious pulmonary complications (LONIPCs) occurring beyond 3 months after allogeneic stem cell transplantation (allo-SCT) have become recognized as life-threatening complications, and they reduce the recipient's quality of life. However, the pathogenesis and optimal treatment for LONIPCs are still unclear. In this study, we retrospectively analyzed the incidence and outcome of LONIPCs among allo-SCT recipients. Between October 1993 and September 2001, 96 patients underwent allo-SCT and 76 patients who survived and were free of disease for more than 3 months after SCT were enrolled. Among the 76 patients, 18 patients (23.7%) developed LONIPCs at a median interval of 227 days after allo-SCT (range, 91-1105 days). The patients with LONIPCs were subclassified into those with bronchiolitis obliterans (BO) (6 patients), with interstitial pneumonia (IP) (11 patients), or with both BO and IP (1 patient). The presence of extensive chronic graft-versus-host disease (GVHD) was significantly associated with the development of LONIPCs (P =.0008). Liver or skin involvement in chronic GVHD was not associated, but sicca syndrome was significantly associated with the development of LONIPCs (P <.0001). Most of the IP patients (58.3%) responded well to immunosuppressive treatment, while BO patients did not respond to the therapy. Eight of the 18 patients with LONIPCs died. The major cause of death was respiratory failure (62.5%). The relapse rate of primary malignant disease in the LONIPC patients was significantly lower than that of non-LONIPC patients (1 of 17 [5.9%] versus 16 of 52 [30.8%]; P =.0387). These results indicate that the development of LONIPCs was strongly associated with chronic GVHD and especially with sicca syndrome and the graft-versus-leukemia (GVL) effect.

Entities:  

Mesh:

Year:  2003        PMID: 12907447     DOI: 10.1182/blood-2002-10-3289

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplant.

Authors:  A L Oh; P Patel; K Sweiss; R Chowdhery; S Dudek; D Rondelli
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

2.  Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation.

Authors:  Matin M Imanguli; Jane C Atkinson; Sandra A Mitchell; Daniele N Avila; Rachel J Bishop; Edward W Cowen; Manuel B Datiles; Frances T Hakim; David E Kleiner; Michael C Krumlauf; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-28       Impact factor: 5.742

Review 3.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

4.  Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation.

Authors:  Fei Gao; Jingyu Chen; Dong Wei; Bo Wu; Min Zhou
Journal:  Front Med       Date:  2017-07-28       Impact factor: 4.592

5.  Xenon-129 MRI detects ventilation deficits in paediatric stem cell transplant patients unable to perform spirometry.

Authors:  Laura L Walkup; Kasiani Myers; Javier El-Bietar; Adam Nelson; Matthew M Willmering; Michael Grimley; Stella M Davies; Christopher Towe; Jason C Woods
Journal:  Eur Respir J       Date:  2019-05-02       Impact factor: 16.671

6.  Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation.

Authors:  Amin Alousi; Somnath Ghosh; David Rice; Cesar Moran; John T Manning; Cesar Iliescu; Sharon Hymes; Stella Kim; Lara Bashoura; Steven Kornblau; Burton F Dickey
Journal:  BMJ Case Rep       Date:  2011-02-23

7.  Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation.

Authors:  Filippo Milano; Margaret A Au; Michael J Boeckh; H Joachim Deeg; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-22       Impact factor: 5.742

8.  [Complications after allogeneic bone marrow and stem cell transplantation].

Authors:  E Wollmer; A Neubauer
Journal:  Internist (Berl)       Date:  2014-05       Impact factor: 0.743

9.  ACE deletion polymorphism is associated with a high risk of non-infectious pulmonary complications after stem cell transplantation.

Authors:  Mitsuki Miyamoto; Makoto Onizuka; Shinichiro Machida; Masako Toyosaki; Jun Amaki; Yasuyuki Aoyama; Hidetsugu Kawai; Ai Sato; Naoki Hayama; Yoshiaki Ogawa; Hiroshi Kawada; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2013-12-21       Impact factor: 2.490

10.  Living-donor single lobe lung transplantation for bronchiolitis obliterans from mother to child following previous allogeneic hematopoietic stem cell transplantation from the same donor.

Authors:  Koichi Oshima; Akira Kikuchi; Shinji Mochizuki; Masaomi Yamane; Hiroshi Date; Ryoji Hanada
Journal:  Int J Hematol       Date:  2009-10-29       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.